These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30710757)

  • 1. Univariate and classification analysis reveals potential diagnostic biomarkers for early stage ovarian cancer Type 1 and Type 2.
    Marcišauskas S; Ulfenborg B; Kristjansdottir B; Waldemarson S; Sundfeldt K
    J Proteomics; 2019 Mar; 196():57-68. PubMed ID: 30710757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study.
    Kandimalla R; Wang W; Yu F; Zhou N; Gao F; Spillman M; Moukova L; Slaby O; Salhia B; Zhou S; Wang X; Goel A
    Clin Cancer Res; 2021 Aug; 27(15):4277-4286. PubMed ID: 34035068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor in ovarian cyst fluid.
    Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; Boonstra H; Sweep CG
    Cancer; 2001 Jan; 91(2):371-7. PubMed ID: 11180084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
    Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
    PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
    Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
    Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR-FTIR spectroscopy coupled with variable selection methods.
    Lima KM; Gajjar KB; Martin-Hirsch PL; Martin FL
    Biotechnol Prog; 2015; 31(3):832-9. PubMed ID: 25832726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
    Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
    Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
    El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
    Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.
    Petri AL; Simonsen AH; Høgdall E; Christensen IJ; Kjaer SK; Yip C; Risum S; Pedersen AT; Hartwell D; Fung ET; Høgdall C
    Proteomics Clin Appl; 2010 Mar; 4(3):304-14. PubMed ID: 21137051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.